Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 1.00 |
| ▸ | BRD2 | P25440 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 2/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 2/20 | 1.00 |
| ▸ | BUB1B | O60566 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | WEE1 | P30291 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163083 | 1.00 | BRD4 (1.00) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL29432552 | 1.00 | BRD4 (1.00) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL14536137 | 0.94 | BRD4 (0.89) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL31163086 | 0.92 | BRD4 (0.85) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL271198 | 0.92 | BRD4 (0.85) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL30306487 | 0.91 | BRD4 (1.00) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL17526335 | 0.91 | BRD4 (1.00) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL263665 | 0.91 | BRD4 (0.84) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL17526085 | 0.91 | BRD4 (1.00) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL270925 | 0.91 | BRD4 (0.83) | BRD4JAK2FLT3JAK1BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | claimed |
| CN-119874724-A | Novel recruitment element of ubiquitin ligase and application thereof | 深圳领济生物科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-12215355-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-04 | — | — | US | claimed |
| EP-4486348-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| CN-118804751-A | New compounds and treatment of renal cell carcinoma | 巴什生物技术公司 | 2024-10-18 | — | — | CN | claimed |
| EP-4444870-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| US-20220235327-A1 | PANCREATIC DIFFERENTIATION | VERTEX PHARMACEUTICALS INCORPORATED | 2022-07-28 | — | — | US | claimed |
| WO-2022072238-A1 | TARGETING POLYCYTHEMIA VERA (PV)-INITIATING CELLS BY BLOCKING LEUKOTRIENE BINDING TO THEIR RECEPTORS | UNIVERSITY OF MASSACHUSETTS (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022062356-A1 | MEDICINE FOR TREATING OR PREVENTING DISEASES RELATED TO ACTIVITY OF LRRK2 KINASE OR ABNORMAL LRRK2 MUTANT KINASE | 广州智睿医药科技有限公司 | 2022-03-31 | — | — | WO | claimed |
| US-20220074941-A1 | HSP90 COMBINATION THERAPY | SLOAN KETTERING INST CANCER RES (US) | 2022-03-10 | — | — | US | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | claimed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | claimed |
| CN-112225703-A | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity | 广州智睿医药科技有限公司 | 2021-01-15 | — | — | CN | claimed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | claimed |
| US-9238030-B2 | Methods for treatment of diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia | BETA CAT PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | claimed |
| CN-104797267-A | Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof | DEL MAR PHARMACEUTICALS | 2015-07-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | BRD4 1177/4885JAK2 1/4885FLT3 78/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | BRD4 699/4885JAK2 3633/4885FLT3 2326/4885 |
| US-20220074941-A1 | HSP90 COMBINATION THERAPY | HSP90AB1, HSP90AB2P, HSP90B1 | BRD4 1138/4885JAK2 723/4885FLT3 1684/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | BRD4 2054/4885JAK2 1/4885FLT3 171/4885 |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | BRD4 2186/4885JAK2 1549/4885FLT3 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.